Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 18/20 | 0.83 |
| ▸ | BCL2L1 | Q07817 | 7/20 | 0.76 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.76 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.76 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523796 | 1.00 | BCL2 (0.83) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL523452 | 0.94 | BCL2 (0.87) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL523451 | 0.94 | BCL2 (0.87) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL29657405 | 0.93 | BCL2 (0.89) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1700182 | 0.93 | BCL2 (0.89) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1700179 | 0.93 | BCL2 (0.89) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1701495 | 0.93 | BCL2 (0.89) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1700715 | 0.92 | BCL2 (0.92) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL30313839 | 0.92 | BCL2 (0.92) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1700720 | 0.92 | BCL2 (0.92) | BCL2BCL2L1MCL1TMEM97BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277291-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20190315737-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3312178-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3091017-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170096424-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3091017-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9403822-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2575463-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9006247-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2575463-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120028925-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011150016-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028925-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20200277291-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20190315737-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20170096424-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.